This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter.

Today, a brief rundown of news from Merck & Co. and Roche, as well as updates from Sangamo Therapeutics, UCB and Catalent that you may have missed.

Merck & Co. will pay $30 million upfront to acquire Modifi Biosciences, a Yale University spinout developing small molecule drugs for cancer. Founded in 2021, Modifi focuses on DNA repair defects in cancer cells, specifically one repair protein known as MGMT for short. Shareholders in Modifi could receive up to $1.3 billion in additional payments if certain, unspecified milestones are met. — Ned Pagliarulo

Sales of Sarepta Therapeutics’ Duchenne muscular dystrophy gene therapy Elevidys outside of the U.S. reached 137 million Swiss francs, or about $156 million, over the first nine months of the year, the company’s international partner Roche said Wednesday. Those sales came from five ex-U.S. countries where Elevidys is also approved. A decision is expected in the EU next year, and Roche has submitted applications in several other countries. The Swiss group cited Elevidys, along with multiple sclerosis shot Ocrevus, as one of its key growth drivers in neurology, which showed a sales increase of 14% to 7 billion francs over the same period in 2023. — Jonathan Gardner

Shares in Sangamo Therapeutics rose Tuesday after the company said it has secured agreement from the Food and Drug Administration on a path to filing its experimental Fabry disease treatment for approval. According to the biotechnology company, regulators agreed that a measure of kidney function could be used as a surrogate endpoint to ask it for accelerated clearance of the gene therapy, dubbed isaralgagene civaparvovec or ST-920. Sangamo expects to have the necessary data by the first half of next year, setting up a submission in the latter half of 2025 — some three years earlier than the company had been planning. — Ned Pagliarulo

Roche has returned to UCB rights to an experimental Alzheimer’s medicine UCB had licensed to the Swiss pharmaceutical company in 2020. The company confirmed Roche’s termination of the collaboration in a statement Tuesday announcing the planned presentation of Phase 2 study results for the drug, bepranemab, at an upcoming medical meeting. Tested in people with prodromal or mild Alzheimer’s, bepranemab is designed to target a protein known as tau in the brain. — Ned Pagliarulo